New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For HON;CEO;CLDX;IN;ZGNX;NXY;MCD From The Last 14 Days
Check below for free stories on HON;CEO;CLDX;IN;ZGNX;NXY;MCD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 16, 2014
12:47 EDTZGNXOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday as the earnings season picks up steam. Stocks began the session sharply higher, with the market attempting to extend the rally that began on Monday. The move upward comes in spite of the dayís housing data coming in below expectations. This afternoon, investors will be watching the Fedís Beige Book report in hopes it provides evidence that the economy is strengthening. ECONOMIC EVENTS: In the U.S., housing starts in March were up 2.8% from the prior month to a rate of 946K, versus expectations for an increase of 7%. Building permits were down 2.4% to a 990K rate, versus expectations for a decline of 0.4%. Industrial production rose 0.7% in March, which was ahead of the 0.5% forecast. The Fedís Beige Book report, which includes anecdotal reports on business conditions in the various Fed districts, is due out at 2:00 pm ET. In China, data showed its economy grew 7.4% in the first quarter from a year earlier, providing relief after recent signs that growth in the world's second largest economy has been slowing. COMPANY NEWS: Shares of Bank of America (BAC) were down over 2% near midday after the company reported a first quarter loss of 5c per share, which was influenced by $6B in legal charges. The $6B in litigation expense, which was related to a previously announced settlement with the Federal Housing Finance Agency and added reserves for other legacy mortgage-related matters, hurt the banks earnings by about 40c per share... Yahoo (YHOO) rose more than 6% after reporting first quarter profit and sales last night that beat expectations. A great deal of attention was also paid to the 66% year-over-year increase in revenue reported by Alibaba, the Chinese group of e-commerce sites in which Yahoo has a 24% stake. This morning, Wells Fargo upgraded its rating on Yahoo to Outperform from Market Perform and raised its price target range for shares to $45-$47 from $38-$40, while Jefferies assumed coverage of Yahoo and also raised its rating on the stock. MAJOR MOVERS: Among the notable gainers was SodaStream (SODA), which surged 9% after an Israeli website said that the company was in talks to sell a 10% or greater stake to a big name company such as PepsiCo (PEP), Dr Pepper Snapple (DPS), or Starbucks (SBUX). Also higher was drugmaker Zogenix (ZGNX), which gained nearly 10% after confirming that a judge prevented a ban on sales of the company's Zohydro pain medication in Massachusetts. Among the noteworthy losers was Agnico Eagle Mines (AEM), which fell 7.5% after agreeing to jointly acquire Osisko Mining in partnership with Yamana Gold (AUY). Yamana shares were also down 3%. Also lower following their earnings reports were ADTRAN (ADTN), which fell nearly 6%, and CSX (CSX), which dropped about 3%. INDEXES: Near midday, the Dow was up 124.14, or 0.76%, to 16,386.70, the Nasdaq was up 37.86, or 0.94%, to 4,072.02, and the S&P 500 was up 13.52, or 0.73%, to 1,856.50.
09:28 EDTZGNXOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTZGNXZogenix rises 9%
Zogenix is up 9%, or 21c, to $2.55
April 15, 2014
18:58 EDTZGNXOn The Fly: After Hours Movers
Subscribe for More Information
16:07 EDTZGNXZogenix confirms reversal of Zohydro sales ban in Massachusetts
Subscribe for More Information
15:33 EDTZGNXZogenix wins reversal of Zohydro sales ban in Mass., Boston Globe says
A federal judge ruled that Massachusetts cannot block sales of Zogenix's Zohydro in the state, as had been previously ordered by Governor Deval Patrick, reports The Boston Globe. Reference Link
14:33 EDTZGNXJudge strikes down ban on Zogenix's Zohydro, Boston Globe says
Subscribe for More Information
08:19 EDTCLDXLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 9, 2014
09:11 EDTZGNXOn The Fly: Pre-market Movers
Subscribe for More Information
09:00 EDTZGNXZogenix rises 8.9%
Zogenix is up 8.9%, or 23c, to $2.82
05:16 EDTZGNXZogenix requested order staying the ban of Zohydro in MA
Today Zogenix presented its case in U.S. District Court in Boston requesting an immediate order staying the ban on the FDA-approved prescription drug product, Zohydro ER extended-release capsules, entered on March 27, by Massachusetts Governor Deval Patrick. A follow-up hearing has been scheduled for Monday, April 14. The company will continue to monitor, evaluate and take appropriate actions in all states specific to Zohydro ER to ensure that all FDA-approved Schedule II prescription opioids covered by the FDA mandated Risk Evaluation Mitigation Strategy for extended-release and long-acting opioid analgesics receive equal treatment for any rules that impact patient access and prescribing.
April 7, 2014
16:15 EDTZGNXZogenix files suit against Massachusetts to block ban of Zohydro ER
Subscribe for More Information
16:02 EDTCLDXCelldex says CDX-014 to enter clinical development
Celldex Therapeutics reported results of preclinical studies evaluating the anti-tumor activity of CDX-014 against a variety of cell lines. Based on the results, CDX-014 will enter clinical development. CDX-014 is an antibody drug conjugate that targets the protein TIM-1. "The data presented today confirm that CDX-014 effectively targets the tumor marker TIM-1 in vitro and elicits significant anti-tumor activity in key models. We are currently completing manufacturing and IND-enabling studies and anticipate that CDX-014 will enter Phase 1 clinical studies in renal cell carcinoma and potentially other TIM-1 expressing tumors in 2015," said Tibor Keler, senior VP and Chief Scientific Officer of Celldex.
09:39 EDTHONHoneywell announces CFO to retire, Vice Chairmen promoted
Subscribe for More Information
06:31 EDTCEOCNOOC mulls sale of $3.1B Bridas stake, Bloomberg says
Subscribe for More Information
April 4, 2014
09:50 EDTCLDXCelldex management to meet with Guggenheim
Meetings to be held in New York on April 10-11 hosted by Guggenheim.
06:54 EDTMCDMcDonald's ceases work in Crimea, Reuters says
Subscribe for More Information
April 3, 2014
08:27 EDTCLDXLeerink's biotech analyst holds a dinner meeting update
Biotech Analyst Liang holds an update from the AACR's Annual Meeting to discuss some of the presentations including PFE/AMGN's Palbociclib, PBYI/PFE's Neratinib, as well as other new agents for breast cancer from LLY, MDVN and CLDX, in San Diego on April 7 at 9 pm.
08:11 EDTCLDXCelldex to present CDX-014 preclinical proof of concept data at AACR
Celldex Therapeutics announced that data from preclinical studies evaluating the anti-tumor activity of the antibody-drug conjugate CDX-014 will be presented at the American Association of Cancer Research, or AACR, Annual Meeting 2014 in San Diego, California, April 5-9. CDX-014 targets the protein TIM-1, which is upregulated in several cancers, including renal and ovarian carcinomas.
06:34 EDTMCDStates moving on minimum wage hikes, NY Times says
Since President Obama called for an increase in the federal minimum wage 14 months ago, seven states and Washington, DC have passed such an increase, according to The New York Times. Meanwhile, 34 other state legislatures have started debating the issue and activists in another eight states are looking to get proposals for minimum wage increases on voter ballots, the newspaper stated. Companies that could be affected by minimum wage increases include McDonald's (MCD), Burger King (BKW), Wendy's (WEN), Jack in the Box (JACK), Dunkin Donuts (DNKN), and Sonic Corporation (SONC). Reference Link
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use